Item 8.01. Other Events.

As previously disclosed in the Current Report on Form 8-K filed by K-V Pharmaceutical (the "Company") with the U.S. Securities and Exchange Commission (the "SEC") on September 15, 2009, the Company on September 14, 2009 received an action by written consent of stockholders, which written consents were supplemented on October 28, 2009 (the "Written Consent"), relating to the adoption by certain stockholders of certain amendments to the Company's By-Laws (the "Amendments"). The Company had retained IVS Associates, Inc. in connection with the receipt of the Written Consent to serve as inspector of elections to tally the votes represented by the Written Consent.
On November 13, 2009, the inspector of elections certified that the votes represented by the Written Consent are sufficient to approve the matters set forth in the Written Consent.
The Company intends to file with the SEC a Schedule 14C Information Statement regarding the Amendments. After the SEC review period has been satisfied, the Company will distribute to the Company's stockholders such Schedule 14C Information Statement to notify them of the Amendments in accordance with the rules and regulations of the SEC. Pursuant to the rules and regulations of the SEC, the Schedule 14C Information Statement must be sent to stockholders at least 20 calendar days prior to the earliest date on which the proposed corporate action may be taken.
A copy of the press release issued by the Company on November 13, 2009 in connection with the foregoing is attached hereto as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release, dated November 13, 2009*

* Filed herewith

---